Format

Send to

Choose Destination
Cell Death Dis. 2016 Oct 27;7(10):e2432. doi: 10.1038/cddis.2016.330.

Melatonin enhances sensitivity to fluorouracil in oesophageal squamous cell carcinoma through inhibition of Erk and Akt pathway.

Lu YX1,2, Chen DL1,2, Wang DS1,2, Chen LZ1,2, Mo HY1, Sheng H1, Bai L1,2, Wu QN1, Yu HE1,2, Xie D1, Yun JP1,3, Zeng ZL1, Wang F1,2, Ju HQ1, Xu RH1,2.

Author information

1
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
2
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
3
Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

Abstract

Oesophageal squamous cell carcinoma (ESCC) is the sixth most common cause of cancer-associated death in the world and novel therapeutic alternatives are urgently warranted. In this study, we investigated the anti-tumour activity and underlying mechanisms of melatonin, an indoleamine compound secreted by the pineal gland as well as naturally occurring plant products, in ESCC cells and revealed that melatonin inhibited proliferation, migration, invasion and induced mitochondria-dependent apoptosis of ESCC cells in vitro and suppressed tumour growth in the subcutaneous mice model in vivo. Furthermore, after treatment with melatonin, the expressions of pMEK, pErk, pGSK3β and pAkt were significantly suppressed. In contrast, treatment of the conventional chemotherapeutic drug fluorouracil (5-Fu) resulted in activation of Erk and Akt, which could be reversed by co-treatment with melatonin. Importantly, melatonin effectively enhanced cytotoxicity of 5-Fu to ESCC in vitro and in vivo. Together, these results suggested that inhibition of Erk and Akt pathway by melatonin have an important role in sensitization of ESCC cells to 5-Fu. Combined 5-Fu and melatonin treatment may be appreciated as a useful approach for ESCC therapy that warrants further investigation.

PMID:
27787516
PMCID:
PMC5133993
DOI:
10.1038/cddis.2016.330
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center